As summarized in Figure 1, the suspicion of AIHA should be raised in patients receiving CPIs who display Hb decrease along with altered hemolytic markers (which should be therefore monitored in these patients). The gene discussed is GSTM1; the disease is autoimmune hemolytic anemia.